After a slow start to the year, merger and acquisition activity in the drug industry could be about to pick up – especially with drug companies having more than $500 billion to spend. Here are the 22 drug companies that analysts at Jefferies believe could be M&A targets. CLICK HERE.
Drug Companies Have More Than $500 Billion To Spend – And These 22 Companies Could Be Their Targets
- by Ashley Hayes